RxDoctor Payments Data

Richard Yee, MD

Ophthalmology · Bellaire, TXNPI 1205817764

Payments from drug & device makers

$205,628in general payments, 2019–2025

Across 386 payments — averaging $532.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$190K
  • Novartis$11K
  • AbbVie$1K
  • Mallinckrodt Hospital Products Inc.$825
  • Amgen$475
  • Shire North American Group Inc$293
  • plus $1K from 13 others
$60,141in research payments, 2019–2025

Across 1 payment — averaging $60,141 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bausch & Lomb Americas Inc.$60K

What the payments were for

  • Speaking & faculty fees$164,05084%
  • Travel & lodging$21,58211%
  • Food & beverage$8,7404%
  • Education$2000%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$205,628 in reported general payments places this provider in the 90th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$136,217
Medicare patients
344
Services billed
1,334

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MieboPerfluorohexyloctane/Pf42$34,574
XiidraLifitegrast22$25,944
Cyclosporine28$23,668
RestasisCyclosporine17$19,241
RhopressaNetarsudil Mesylate54$16,744
Travoprost30$8,275
TyrvayaVarenicline Tartrate11$6,435
Prednisolone Acetate96$3,014
MoxifloxacinMoxifloxacin Hcl121$2,654
Loteprednol Etabonate12$1,513
Pilocarpine Hcl14$947
Ketorolac Tromethamine44$726
Acyclovir13$289
Latanoprost21$195
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha18$145

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Miebo, Xiidra$190,053$60,51964 claims
AbbVieRestasis$1,344$19,24117 claims
Aerie Pharmaceuticals, Inc.Rhopressa$67$16,74454 claims
Oyster Point Pharma, Inc.Tyrvaya$23$6,43511 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$282$1,51312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Bellaire

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →